NEW YORK (GenomeWeb News) – Hologic has completed its $3.8 billion acquisition of Gen-Probe following approval from Gen-Probe's shareholders yesterday.

Gen-Probe will now become a wholly owned subsidiary of Hologic. Carl Hull, the chairman and CEO of Gen-Probe, will stay with Hologic for at least 15 months to direct the combined diagnostic operations, as the firms previously announced.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.